NightHawk Biosciences Inc (NHWK)

[dia76ca]

The company has set a clear goal. On slide #5 of the March 2017 company presentation it says,"Only ~25% of patients respond to checkpoint therapies alone" and then states "We hope to DOUBLE the number of patients who respond to checkpoints."http://content.stockpr.com/heatbio/media/3848f8c4739fa3f88470f3337f8369f9.pdf

So far using HS-110 alone with Opdivo they have announced data which meets or exceeds this goal. Undoubtedly they now have an even larger sample size. They will know the latest data as will interested international pharmaceutical companies under confidentiality agreements. And the company has the second generation ComPACT technology which showed even better results in preclinical models. And they are soon to reacquire PTX-25 which they claim is the "best in class co-stimulator". Both of these technologies used in combination with the basic gp-96 technology should significantly improve trial results!

But what really is very exciting is the Shattuck Lab news that "an international pharmaceutical company" has acquired a "considerable interest" in a private preclinical offering. Shattuck Labs is a spinoff of HTBX and licences its technology from HTBX. This could be the first step in an early partnership or buy-out. We have to wait for more news...but my opinion is that there is a lot of good news coming. Good luck to us all.